The recent unexpected death of a young man undergoing experimental gene therapy for a rare liver disease may have serious repercussions for companies in the field.
Probably most worried are those firms using adenoviral vectors to transfer genes into cells. That was the type of vector deployed in late September at the University of Pennsylvania ...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?